Cargando…

Successful Management of a Patient with Refractory Primary Central Nervous System Lymphoma by Zanubrutinib

Primary central nervous system lymphoma (PCNSL) is a rare subtype of extranodal non-Hodgkin lymphoma, and the most frequent histological type is diffuse large B‐cell lymphoma (DLBCL). Bruton’s tyrosine kinase inhibitor (BTKi) has shown clinical activity in DLBCL. We herein report a 53-year-old man w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Qiansong, Wang, Jing, Lv, Chenglan, Xu, Jingyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163630/ https://www.ncbi.nlm.nih.gov/pubmed/34079282 http://dx.doi.org/10.2147/OTT.S309408

Ejemplares similares

P1143: ZANUBRUTINIB PLUS CYTARABINE IN PATIENTS WITH REFRACTORY/RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
por: Lin, Zhiguang, et al.
Publicado: (2023)

Primary central nervous system lymphoma in the United States, 1975–2017
por: Lv, Chenglan, et al.
Publicado: (2022)

Zanubrutinib in the Maintenance Treatment of Elderly People with Primary Central Nervous System Lymphoma: A Report of 2 Cases
por: Liu, Ying, et al.
Publicado: (2023)

P1223: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZRMA REGIMEN（ZANUBRUTINIB, RITUXIMAB, METHOTREXATE AND CYTARABINE)
por: Tang, Y.
Publicado: (2022)

PB2315: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZR OR ZRM REGIMEN (ZANUBRUTINIB, RITUXIMAB, METHOTREXATE)
por: Teng, Yue, et al.
Publicado: (2023)

P1197: BRUTON’S TYROSINE KINASE INHIBITOR ZANUBRUTINIB IN RELAPSED/REFRACTORY PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF CENTRAL NERVOUS SYSTEM: A PHASE II TRIAL
por: Wang, Yali, et al.
Publicado: (2023)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

PB2337: SHORT-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB COMBINED WITH POMALIDOMIDE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM LYMPHOMA
por: Zhang, Zhipeng, et al.
Publicado: (2023)

Salvage Therapy for Refractory Aids-Related Primary Central Nervous System Lymphoma
por: Ferro, Hugo, et al.
Publicado: (2012)

Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma
por: Yang, Haiyan, et al.
Publicado: (2022)

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study
por: Opat, Stephen, et al.
Publicado: (2023)

Pretreatment diffusion-weighted imaging for prediction of relapsed and refractory primary central nervous system lymphoma
por: Chien, Hsi-Cheng, et al.
Publicado: (2023)

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials
por: Zhou, Keshu, et al.
Publicado: (2021)

Combination Therapy with Rituximab and Temozolomide for Recurrent and Refractory Primary Central Nervous System Lymphoma
por: Murakami, Mineko, et al.
Publicado: (2011)

ML-21 Tirabrutinib monotherapy for relapsed/refractory primary central nervous system lymphoma
por: Kobayashi, Keiichi, et al.
Publicado: (2020)

Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review
por: Nepal, Gaurav, et al.
Publicado: (2022)

Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review
por: Alsuhebany, Nada, et al.
Publicado: (2023)

Primary Central Nervous System Lymphoma
por: Dong, Yan-Hong, et al.
Publicado: (2016)

Primary central nervous system lymphoma
por: Gloghini, Annunziata, et al.
Publicado: (2015)

Primary central nervous system lymphoma
por: Löw, Sarah, et al.
Publicado: (2018)

Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
por: Song, Yuqin, et al.
Publicado: (2023)

Recent advances in the management of primary central nervous system lymphoma
por: Choi, Yoon Seok
Publicado: (2020)

Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date
por: Sawalha, Yazeed, et al.
Publicado: (2020)

Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia
por: Tam, Constantine S., et al.
Publicado: (2023)

Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma
por: Okita, Yoshiko, et al.
Publicado: (2021)

Zanubrutinib for mantle cell lymphoma, Waldenström’s macroglobulinaemia
Publicado: (2021)

P1163: ZANUBRUTINIB PLUS RITUXIMAB AND LENALIDOMIDE (ZR2) FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Zhang, Xiyuan, et al.
Publicado: (2023)

Primary intercavernous lymphoma of the central nervous system
por: Dultra, Arthur Henrique de Aquino, et al.
Publicado: (2015)

SS-5 Current management of primary central nervous system lymphoma
por: Mishima, Kazuhiko, et al.
Publicado: (2020)

Primary Central Nervous System Lymphoma in Elderly Patients: Management and Perspectives
por: Morales-Martinez, Andrea, et al.
Publicado: (2021)

Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date [Corrigendum]
Publicado: (2020)

Successful Management of Natalizumab-Associated Primary Central Nervous System Lymphoma through Autologous Stem Cell Transplant
por: Moineau-Vallée, Karine, et al.
Publicado: (2020)

Primary Central Nervous System Lymphoma With Systemic Recurrence
por: Pandravada, Sasirekha, et al.
Publicado: (2021)

Molecular characteristics of immunocytes infiltration in primary central nervous system lymphoma
por: Zhang, Linyun, et al.
Publicado: (2022)

ESHAP chemotherapy is efficient in refractory/relapsed primary central nervous system lymphoma: report of four cases
por: Ungur, Rodica, et al.
Publicado: (2015)

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
por: Song, Yuqin, et al.
Publicado: (2022)

Successful rapid drug desensitization to methotrexate in a patient with primary central nervous system lymphoma
por: Song, Kyung Mee, et al.
Publicado: (2018)

A case report of primary central nervous system lymphoma
por: Zeng, Xu, et al.
Publicado: (2020)

Mutational analysis of primary central nervous system lymphoma
por: Bruno, Aurélie, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dj8c9qffootkeat87gongo1is2